Date: 2012-10-23
Type of information: Development agreement
Compound: undisclosed diagnostic kit
Company: Theradiag (France) Sebia (France)
Therapeutic area: undisclosed
Type agreement: development
manufacturing
production
Action mechanism:
Disease: undisclosed
Details: Theradiag, the theranostics and in vitro diagnostics company focused on autoimmune diseases, has just signed a partnership agreement with Sebia. Within the framework of this partnership, Theradiag will play an advisory role in development and will be responsible for the scale-up and production of a future diagnostic kit. According to the terms of the agreement, Theradiag will receive royalties on sales and revenues for future production.
Financial terms:
Latest news:
